BMS raised its full-year 2026 revenue and adjusted EPS guidance.
Iberdomide is launch-ready ahead of its August 17, 2026 PDUFA date.
Mezigdomide has a May 13, 2027 PDUFA date.
Milvexian's atrial fibrillation study is now expected to read out in Q1 2027.
Admilparant's IPF Phase III readout is expected by end-2026, with PPF following a few months later.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Bristol-Myers Squibb Company and 4,900+ companies.